A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes.

Morel, Sandra;Ooms, Annie;Van Pel, Aline;Wölfel, Thomas;Degiovanni, Gérard;et.al.
(1999) International Journal of Cancer — Vol. 83, n° 6, p. 755-759 (1999)

Files

MOREL_IJC1999.pdf
  • Restricted Access
  • Adobe PDF
  • 120.9 KB
Request a copy

Details

Authors
  • Morel, SandraUCLouvain
    Author
  • Ooms, AnnieUliège
    Author
  • Van Pel, AlineUCLouvain
    Author
  • Wölfel, ThomasIII Medizinische Klinik and Poliklinik der Johannes Gutenberg-Universität, Mainz, Germany
    Author
  • van der Bruggen, PierreUCLouvain
    Author
  • Van den Eynde, Benoitorcid-logoUCLouvain
    Author
  • Degiovanni, GérardUliège
    Author
Show more
Abstract
We previously described different cytotoxic T lymphocyte (CTL) clones isolated from the blood lymphocytes of a melanoma patient after in vitro stimulation with autologous tumor cells. These CTL clones recognized at least 2 distinct antigens on the melanoma cells. Here, we show that one of them consists of a peptide derived from tyrosinase and presented by HLA-B35. The peptide is 9 amino acids long and has the sequence LPSSADVEF. It can be presented by the 2 major B35 allelic subtypes, B*3501 and B*3503. As HLA-B35 is one of the most frequent HLA-B specificities, being present in about 20% of Caucasian individuals, it may be a useful target for peptide-based immunotherapy of melanoma.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Morel, S., Ooms, A., Van Pel, A., Wölfel, T., Brichard, V. G., van der Bruggen, P., Van den Eynde, B., & Degiovanni, G. (1999). A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes. International Journal of Cancer, 83(6), 755-759. https://doi.org/10.1002/(SICI)1097-0215(19991210)83:6<755::AID-IJC10>3.0.CO;2-S (Original work published 1999)